#United States #New York #Class Action #The Gross Law Firm #INOVIO Pharmaceuticals

Class Action Filed Against Inovio Pharmaceuticals, Inc.

The Gross Law Firm has announced the filing of a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and the notice is aimed specifically at shareholders who acquired shares during the specified class period from October 10, 2023, to December 26, 2025. This notice comes as a crucial alert to investors, encouraging those affected to consider their options and voice their concerns by registering with the firm before the deadline set for April 7, 2026.

What You Need to Know

Background of the Allegations

During the class action period, the lawsuit accuses the defendants of making materially false or misleading statements about Inovio's manufacturing processes and product timelines. It is claimed that the company had not adequately disclosed deficiencies in the manufacturing of its CELLECTRA device. Consequently, this led to doubts concerning the timely submission of its lead product candidate, INO-3107, to the FDA for evaluation by the second half of 2024.

Additionally, the complaint highlights that Inovio appeared to have insufficient information to substantiate claims regarding INO-3107's candidacy for accelerated approval or priority review from the FDA. Thus, the overall expectations surrounding INO-3107's regulatory and commercial viability were deemed significantly exaggerated. This series of misrepresentations reportedly misled investors and played a substantial role in artificially inflating the company’s stock value.

Class Action Details

For those shareholders who wish to participate in the class action, there are specific steps to follow. Firstly, they are encouraged to register on The Gross Law Firm’s website to ensure they remain updated on the status of the case through a monitoring program created to keep stakeholders informed throughout the litigation process.

It's pivotal that interested shareholders not delay, as the opportunity to enroll and potentially serve as a lead plaintiff is limited to the aforementioned deadline. It’s important to understand that participating in the suit does not obligate investors to any costs, ensuring ease of access to those who wish to seek justice.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a leading name in the realm of class action litigation, particularly concerning investor rights. The firm is dedicated to safeguarding the interests of those who have suffered financial losses due to misleading corporate behaviors. By promoting stringent accountability among publicly traded companies, the firm seeks to rectify the consequences of deceitful business practices that compromise market integrity.

For shareholders of Inovio Pharmaceuticals, this lawsuit presents a valuable opportunity to hold the company accountable for its actions. The firm’s commitment to ethical legal standards is a motivating factor for many investors as they weigh their participation in this class action.

Next Steps for Inovio Shareholders

Registering Your Information

If you purchased INO shares in the mentioned timeframe, it is essential to register your information promptly. By doing so, shareholders can not only monitor developments related to the case but also join in collective efforts towards recovery of losses incurred during the pertinent period. Registration can be completed via the link provided on The Gross Law Firm’s website, facilitating a straightforward process for potential plaintiffs.

Conclusion

In view of the significant allegations against Inovio Pharmaceuticals, Inc., shareholders are urged to take proactive measures in light of the impending deadline. Participation in this class action could pave the way for restitution, reflecting the importance of transparency and accountability in business practices. As a shareholder, taking the time to explore options and act swiftly can be imperative in such unique and crucial circumstances.